SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Matthew Dicks

Principal Scientist

Matt leads the development of a new technology platform applying our proptechnology to design new adenovirus-based vectors to target cancer and infectious diseases.

He joined SpyBiotech in 2017 from King’s College, London where he spent several years researching the virology of HIV. He is a specialist in the development of novel adenovirus-based vaccine vectors - common viruses engineered so that they are non-infectious but can generate a protective immune response.

After taking an undergraduate degree in Biochemistry from Oxford University, Matt moved to the renowned Jenner Institute to complete his doctorate. ChAdOx1, the novel chimpanzee adenovirus vector he created there, is patent protected in multiple territories and is the platform technology upon which the Oxford-Astrazeneca COVID-19 vaccine (VaxzevriaTM) is based.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline